Catalog snapshot
- 38Human RCT*
- 23Human other
- 5Animal
- 1In vitro
- 25Review
- 3Syst. review
- 19Other
- 114Total
- 21Registered trials
*Record counts by study type from the PHX research catalog (PubMed, ClinicalTrials.gov, Europe PMC). Human RCT counts include registry entries. Labels are auto-classified from abstracts.
What the Research Suggests, in Plain Language
Tesamorelin is a lab-made compound that prompts the body to release more of its own growth hormone. It is a prescription medicine (Egrifta) approved by the U.S. Food and Drug Administration for one narrow use: reducing excess belly fat in adults with HIV who have a fat-distribution condition called lipodystrophy.
- In people, large trials with a placebo comparison found that adults in that HIV group lost more deep belly fat (fat around the organs) than people given placebo.
- Later, smaller trials in people with HIV also looked at fat in the liver.
- Very little research has looked at people outside that HIV group, and there are very few animal studies.
In short: these results apply to the specific patient group that was studied. They do not show that tesamorelin is safe or effective for any other use.
Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved (as Egrifta) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
What the Research Actually Presents
Phase 3 randomized controlled trials that supported FDA approval (NEJM 2007, 412 patients, PMID 18057338, and subsequent trials): Participants with HIV-associated lipodystrophy showed greater reductions in visceral adipose tissue (deep abdominal fat) compared with placebo.
JCEM 2010 pooled analysis of two phase 3 trials (n=543; PMID 20554713) confirmed the visceral fat reduction finding in the indicated population.
Later trials in HIV populations (Massachusetts General Hospital and others), including a randomized trial in non-alcoholic fatty liver disease in HIV (61 patients; PMID 31611038), reported effects on visceral and liver fat in those populations.
Data outside the HIV-associated lipodystrophy population are limited.
What the Research Suggests
The phase 3 trials that led to FDA approval report that tesamorelin reduced excess abdominal (visceral) fat more than placebo in adults with HIV-associated lipodystrophy under the conditions studied.
These findings are specific to the approved indication and population. Evidence outside that population is limited.
Mechanism and Signaling Pathways (as described in the literature)
As a GHRH analog, tesamorelin is described as stimulating growth hormone (GH) release from the pituitary via the GHRH receptor. The approved-use trials report downstream effects on visceral adipose tissue in the HIV population studied.
Research Landscape
Catalog: 114 records — 38 human randomized controlled trials (RCTs, including registry entries), 23 other human, 5 animal, 1 in-vitro, 25 reviews, 3 systematic reviews/meta-analyses, 19 other. 21 ClinicalTrials.gov entries.
Key Studies
- Falutz J et al. 2007 (NEJM): phase 3 randomized, placebo-controlled trial in HIV-associated abdominal fat accumulation; 412 patients (PMID 18057338).
- Falutz J et al. 2010 (JCEM): pooled analysis of two phase 3 trials; 543 patients (PMID 20554713).
- Falutz J et al. 2008: long-term safety extension (PMID 18690162).
- Stanley TL et al. 2019 (Lancet HIV): randomized, double-blind trial in HIV-associated non-alcoholic fatty liver disease; 61 patients (PMID 31611038).
Safety Findings Reported in the Studies
In the 2007 phase 3 trial, adverse events did not differ significantly between groups, but more participants in the tesamorelin group withdrew because of an adverse event (PMID 18057338). Data outside the approved population are limited.
Limitations and Evidence Gaps
Little published data outside the HIV-associated lipodystrophy indication. Animal studies are minimal.
Regulatory Status
FDA-approved (Egrifta, November 2010) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Not approved for other uses. Prohibited by the World Anti-Doping Agency (WADA) as a growth hormone-releasing factor.
References
Falutz J et al. NEJM 2007 (PMID 18057338). Falutz J et al. AIDS 2008 (PMID 18690162). Falutz J et al. JCEM 2010 (PMID 20554713). Stanley TL et al. Lancet HIV 2019 (PMID 31611038). Additional phase 3 and meta-analysis publications listed in the research catalog.
Evidence reviewed through November 2026 (PHX research catalog snapshot of PubMed, ClinicalTrials.gov and Europe PMC).
Frequently Asked Questions
Are there human studies on tesamorelin?
Yes. Phase 3 randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy supported its approval, including a 412-patient trial (PMID 18057338) and a pooled analysis of 543 patients (PMID 20554713).
Is tesamorelin FDA approved?
Yes, for one use only. It was approved as Egrifta in November 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for other uses.
Is there research on tesamorelin outside HIV?
Very little. Published data outside HIV-associated lipodystrophy are limited, and animal studies are minimal.
Answers summarize the PHX research catalog and are not medical advice.
Linked sources
Records from the PHX research catalog that correspond to the studies discussed above. Links open PubMed or ClinicalTrials.gov.
- Metabolic effects of a growth hormone-releasing factor in patients with HIV
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial